Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1449-1457; doi:10.1093/jnci/93.19.1449
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Morrow, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Right arrow Articles by Morrow, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1449-1457, October 3, 2001
© 2001 Oxford University Press

REVIEW

Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease

V. Craig Jordan, Susan Gapstur, Monica Morrow

Affiliations of authors: V. C. Jordan (Robert H. Lurie Comprehensive Cancer Center), S. Gapstur (Department of Preventive Medicine), M. Morrow (Department of Surgery), Northwestern University Medical School, Chicago, IL.

Correspondence to: V. Craig Jordan, Ph.D., D.Sc., Robert H. Lurie Comprehensive Cancer Center, 710 North Fairbanks Court, Olson Pavilion 8258, Chicago, IL 60611 (e-mail: vcjordan{at}nwu.edu).

The recognition of selective estrogen receptor modulation in the laboratory has resulted in the development of two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, for clinical application in healthy women. SERMs are antiestrogenic in the breast but estrogen-like in the bones and reduce circulating cholesterol levels. SERMs also have different degrees of estrogenicity in the uterus. Tamoxifen is used specifically to reduce the incidence of breast cancer in premenopausal and postmenopausal women at risk for the disease. In contrast, raloxifene is used specifically to reduce the risk of osteoporosis in postmenopausal women at high risk for osteoporosis. The study of tamoxifen and raloxifene (STAR) trial is currently comparing the ability of these SERMs to reduce breast cancer incidence in high-risk postmenopausal women. There is intense interest in understanding the molecular mechanism(s) of action of SERMs at target sites in a woman's body. An understanding of the targeted actions of this novel drug group will potentially result in the introduction of new multifunctional medicines with applications as preventive agents or treatments of breast cancer and endometrial cancer, coronary heart disease, and osteoporosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Carreras, S. Turner, V. Paharkova-Vatchkova, A. Mao, C. Dascher, and S. Kovats
Estradiol Acts Directly on Bone Marrow Myeloid Progenitors to Differentially Regulate GM-CSF or Flt3 Ligand-Mediated Dendritic Cell Differentiation
J. Immunol., January 15, 2008; 180(2): 727 - 738.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. C. Jordan
SERMs: Meeting the Promise of Multifunctional Medicines
J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
R. T Chatterton Jr, J. Zujewski, E. T Mateo, J. Eng-Wong, and V C. Jordan
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
J. Endocrinol., December 1, 2006; 191(3): 599 - 604.
[Abstract] [Full Text] [PDF]

Home page
 GENES CELLSHome page
Y. Ogura, M. Azuma, Y. Tsuboi, Y. Kabe, Y. Yamaguchi, T. Wada, H. Watanabe, and H. Handa
TFII-I down-regulates a subset of estrogen-responsive genes through its interaction with an initiator element and estrogen receptor {alpha}
Genes Cells, April 1, 2006; 11(4): 373 - 381.
[Abstract] [Full Text] [PDF]

Home page
 Reproductive SciencesHome page
S. C.J.P. Gielen, C. W. Burger, L. C.M. Kuhne, P. Hanifi-Moghaddam, and L. J. Blok
Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin
Reproductive Sciences, October 1, 2005; 12(7): e55 - e66.
[Abstract] [PDF]

Home page
 JCOHome page
V. C. Jordan
Chemoprevention in the 21st Century: Is a Balance Best or Should Women Have No Estrogen at All?
J. Clin. Oncol., March 10, 2005; 23(8): 1598 - 1600.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
U. Chatterji, J. E. Riby, T. Taniguchi, E. L. Bjeldanes, L. F. Bjeldanes, and G. L. Firestone
Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells
Carcinogenesis, July 1, 2004; 25(7): 1119 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. T. Pearce, H. Liu, I. Radhakrishnan, M. Abdelrahim, S. Safe, and V. C. Jordan
Interaction of the Aryl Hydrocarbon Receptor Ligand 6-Methyl-1,3,8-trichlorodibenzofuran with Estrogen Receptor {alpha}
Cancer Res., April 15, 2004; 64(8): 2889 - 2897.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
S. Tang, H. Han, and V. B. Bajic
ERGDB: Estrogen Responsive Genes Database
Nucleic Acids Res., January 1, 2004; 32(90001): D533 - 536.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al.
Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Fujita, Y. Kobayashi, O. Wada, Y. Tateishi, L. Kitada, Y. Yamamoto, H. Takashima, A. Murayama, T. Yano, T. Baba, et al.
Full Activation of Estrogen Receptor {alpha} Activation Function-1 Induces Proliferation of Breast Cancer Cells
J. Biol. Chem., July 11, 2003; 278(29): 26704 - 26714.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. H. Arjmandi, D. A. Khalil, B. J. Smith, E. A. Lucas, S. Juma, M. E. Payton, and R. A. Wild
Soy Protein Has a Greater Effect on Bone in Postmenopausal Women Not on Hormone Replacement Therapy, as Evidenced by Reducing Bone Resorption and Urinary Calcium Excretion
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1048 - 1054.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Webb, P. Nguyen, and P. J. Kushner
Differential SERM Effects on Corepressor Binding Dictate ERalpha Activity in Vivo
J. Biol. Chem., February 21, 2003; 278(9): 6912 - 6920.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Wulfkuhle, D. C. Sgroi, H. Krutzsch, K. McLean, K. McGarvey, M. Knowlton, S. Chen, H. Shu, A. Sahin, R. Kurek, et al.
Proteomics of Human Breast Ductal Carcinoma in Situ
Cancer Res., November 15, 2002; 62(22): 6740 - 6749.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. Rivenzon-Segal, R. Margalit, and H. Degani
Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo 13C MRS
Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E623 - E630.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. A. Khalil, E. A. Lucas, S. Juma, B. J. Smith, M. E. Payton, and B. H. Arjmandi
Soy Protein Supplementation Increases Serum Insulin-Like Growth Factor-I in Young and Old Men but Does Not Affect Markers of Bone Metabolism
J. Nutr., September 1, 2002; 132(9): 2605 - 2608.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. C. Jordan, H. Liu, and R. Dardes
Re: Effect of Long-Term Estrogen Deprivation on Apoptotic Responses of Breast Cancer Cells to 17{beta}-Estradiol and The Two Faces of Janus: Sex Steroids as Mediators of Both Cell Proliferation and Cell Death
J Natl Cancer Inst, August 7, 2002; 94(15): 1173 - 1173.
[Full Text] [PDF]

Home page
 JCOHome page
E. P. Winer, C. Hudis, H. J. Burstein, R. T. Chlebowski, J. N. Ingle, S. B. Edge, E. P. Mamounas, J. Gralow, L. J. Goldstein, K. I. Pritchard, et al.
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002
J. Clin. Oncol., August 1, 2002; 20(15): 3317 - 3327.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. C. Kemp, P. W. Fan, and J. C. Stevens
Characterization of Raloxifene Glucuronidation in Vitro: Contribution of Intestinal Metabolism to Presystemic Clearance
Drug Metab. Dispos., June 1, 2002; 30(6): 694 - 700.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
Y. Shang and M. Brown
Molecular Determinants for the Tissue Specificity of SERMs
Science, March 29, 2002; 295(5564): 2465 - 2468.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.